Surgical and pathological outcome, and pathological regression, in patients receiving perioperative atezolizumab in combination with FLOT chemotherapy versus FLOT alone for resectable esophagogastric adenocarcinoma: Interim results from DANTE, a randomized, multicenter, phase IIb trial of the FLOT-AIO German Gastric Cancer Group and Swiss SAKK.Salah-Eddin Al-Batran, Timo Gaiser, Michael Schenk et al.|Journal of Clinical Oncology|2022Cited by 96
A randomized, open-label, phase II/III efficacy and safety study of atezolizumab in combination with FLOT versus FLOT alone in patients with gastric cancer and adenocarcinoma of the oesophagogastric junction and high immune responsiveness: The IKF-S633/DANTE trial, a trial of AIO in collaboration with SAKK.Salah-Eddin Al-Batran, Thorsten Oliver Goetze, Sylvie Lorenzen et al.|Journal of Clinical Oncology|2023Cited by 13
Perioperative atezolizumab in combination with FLOT versus FLOT alone in patients with resectable esophagogastric adenocarcinoma: DANTE, a randomized, open-label phase II trial of the German Gastric Group of the AIO and the SAKKS-E. Al-Batran, Nils Homann, Claudia Pauligk et al.|Annals of Oncology|2019Cited by 8
High rates of hepatocellular carcinoma within two years of starting treatment for chronic hepatitis C with direct antiviral agents but not with PEG-interferon/ Ribavirin (HORRID Study)Fatih Karbeyaz, Alexander Siebenhuener, Beat Müllhaupt et al.|Annals of Oncology|2019Cited by 0